Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02179515|
Recruitment Status : Completed
First Posted : July 2, 2014
Last Update Posted : January 14, 2019
- This cancer vaccine was developed to help teach the body's immune system to attack and destroy cancer cells. It teaches immune cells to target the Brachyury protein. This protein is present in some tumor cells, and it can help tumor cells spread to other parts of the body. Researchers want to see whether the new Brachyury protein vaccine can help treat people with advanced carcinomas.
- To test the safety and effectiveness of giving the MVA-brachyury-TRICOM vaccine to people with cancer.
- Adults ages 18 and over whose type of cancer has not responded to standard therapies who do not have a history of autoimmune diseases and are capable of taking care of themselves.
- Participants will be screened with a medical history and physical exam. They will have blood and urine tests. They may have a computed tomography (CT) scan, a positron emission tomography (PET) scan, and a brain magnetic resonance imaging (MRI) scan. They may have a bone scan. They will have an electrocardiogram (ECG) to test heart rhythm.
- Participants will have visits about every 4 weeks. They will have a physical exam and blood and urine tests. They will be injected with the vaccine under the skin into the upper thigh or around the armpits.
- CT scans or MRI scans will be done at visit 1, after 3 months on study, and again 3 months later if still on the study. Another ECG will be done at their last vaccine visit.
- When participants stop the vaccine, they will return for visits until they recover from any side effects. They will have tests including physical exam, blood tests, scans, and x-rays.
- Participants will be asked to enroll in another study for long-term follow-up.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer Breast Cancer Prostate Cancer Tumors (Others) Ovarian Cancer||Biological: MVA-brachyury- TRICOM||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM)|
|Study Start Date :||June 28, 2014|
|Actual Primary Completion Date :||April 6, 2017|
|Actual Study Completion Date :||February 28, 2018|
Three cohorts will receive MVA-brachyury-TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/ 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
Biological: MVA-brachyury- TRICOM
It is an active cancer immunotherapy administered via subcutaneous injection.
- Safety and tolerability of escalating doses of MVA-brachyury-TRICOM vaccine. [ Time Frame: 2 -3 years ]
- CD8 and CD4 immunologic response as measured by an increase in brachyury-specific T cells. [ Time Frame: 2 -3 years ]
- Evidence of clinical benefit, such as progression-free survival, RECIST criteria, reduction in serum markers, and/or reduction in circulating tumor cells. [ Time Frame: 2 -3 years ]
- Frequency of immune cell subsets in peripheral blood and changes in serum levels of cytokines and antibodies to brachyury. [ Time Frame: 2 -3 years ]
- Correlation of brachyury expression in tissue samples with clinical outcomes. [ Time Frame: 2 -3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02179515
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||James L Gulley, M.D.||National Cancer Institute (NCI)|